Danish drugmaker Novo Nordisk is facing a major challenge to its blockbuster weight-loss drug Wegovy. Booming sales of Wegovy ...

Novo Nordisk remains a strong buy despite share price dip, thanks to its robust drug pipeline, massive market potential, and ...

The market is driving prices on GLP-1 drugs down, and an added benefit is lower spending on food.

A new drug that skips neurons and targets support cells cut weight and improved insulin response in lab animals, without ...

Wegovy and Zepbound - except the weight regain is worse, because of the extreme way in which these medications suppress your ...

In their zeal to “Make America Healthy Again,” Trump administration officials are making statements that some advocacy and ...

Dear E.M.: Obstructive sleep apnea is when a person stops breathing during sleep due to obstruction of their airway. Some ...

Novo Nordisk A/S’s sales showed the weakest growth in four years as the Danish drugmaker loses ground to Eli Lilly & Co. in ...

Key Points Revenue grew 23% year over year (GAAP) in Q2 2025, but missed analyst estimates by $4.1 million (GAAP). The telehealth segment achieved 30.0% revenue growth, with Adjusted EBITDA rising 560 ...

Weight loss and diabetes drugs on the market often do not achieve long-term weight loss for patients. GLP-1 drugs target ...

This maker of weight-loss drugs saw its share price zoom and then crash. The CEO has been replaced. The incoming boss will ...